GlassScriptPhysician profile
Alexander Nicholson
NPI 1497188197
$6,548.89
in general payments reported to CMS, 2019-2025
35 companies · $2,154 in 2025
The $2,154 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $707 · 2023: $1,510 · 2024: $2,178 · 2025: $2,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,755 · Education: $87.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,754.53 |
| Education | $87.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,165.08 | 2022-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $1,030.24 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $636.30 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $506.49 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $401.21 | 2022-2025 | Cuvitru, Takhzyro, Glassia |
| Genentech USA, INC. | $363.46 | 2022-2024 | Xolair |
| Csl Behring | $308.46 | 2022-2025 | Hizentra, Haegarda |
| Optinose US, INC. | $233.79 | 2023-2024 | |
| Grifols USA, LLC | $222.84 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Kaleo, INC. | $184.72 | 2022-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $140.51 | 2023-2025 | |
| Amgen INC. | $133.60 | 2022-2025 | Tezspire |
| Abbvie INC. | $131.47 | 2022-2024 | |
| Pfizer INC. | $113.72 | 2022-2025 | |
| Blueprint Medicines Corporation | $111.92 | 2022-2024 | Ayvakit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $110.43 | 2023-2025 | Orladeyo |
| Pharming Healthcare, INC. | $99.92 | 2022-2025 | Ruconest |
| Organon LLC | $90.73 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $83.53 | 2025 | Neffy |
| Octapharma USA, INC. | $83.36 | 2024 | Panzyga, Octagam Immune Globulin (Human) |
| Leo Pharma INC. | $80.37 | 2022-2023 | Adbry |
| Lilly USA, LLC | $37.25 | 2024-2025 | Jardiance, Ebglyss |
| Covis Pharma Gmbh | $35.30 | 2022 | |
| Kedrion Biopharma, INC. | $31.11 | 2024 | Gammaked, Kedrab, Koate |
| Horizon Therapeutics Plc | $26.31 | 2023 | Actimmune |
| Actelion Pharmaceuticals US, INC. | $24.68 | 2022 | |
| Aerin Medical INC. | $22.74 | 2025 | |
| Sanofi-Aventis U.S. LLC | $22.15 | 2024 | |
| Phadia US INC. | $18.59 | 2023 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.37 | 2022 | |
| Galderma Laboratories, L.P. | $17.92 | 2025 | Nemluvio |
| Azurity Pharmaceuticals, INC. | $16.34 | 2025 | Alvesco |
| Teva Pharmaceuticals USA, INC. | $15.79 | 2022 | |
| Adma Biomanufacturing LLC | $15.41 | 2022 | |
| Mylan Specialty L.P. | $14.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.